Angiotensin receptor neprilysin inhibitor treatment is safe and potentially efficacious in end‑stage hypertrophic cardiomyopathy

Pol Arch Intern Med. 2017 Mar 21;127(3):216-218. doi: 10.20452/pamw.3982. Epub 2017 Mar 21.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aminobutyrates / pharmacology
  • Angiotensin Receptor Antagonists / pharmacology*
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Biphenyl Compounds
  • Cardiomyopathy, Hypertrophic / drug therapy*
  • Drug Combinations
  • Enalapril / pharmacology
  • Humans
  • Neprilysin / antagonists & inhibitors
  • Patient Safety*
  • Tetrazoles / pharmacology
  • Treatment Outcome
  • Valsartan / pharmacology

Substances

  • Aminobutyrates
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Biphenyl Compounds
  • Drug Combinations
  • Tetrazoles
  • Enalapril
  • Valsartan
  • Neprilysin
  • sacubitril and valsartan sodium hydrate drug combination